|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.690 USD | +4.32% |
|
+12.67% | +25.19% |
| 15/01 | Ocugen, Inc. - Special Call | |
| 15/01 | Ocugen Says Gene Therapy Reduced Lesion Growth by 46% in Eye Disease Trial | MT |
EPS & Dividend: Ocugen, Inc.
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.31 | -0.3 | -0.38 | -0.26 | -0.2 | -0.228 | -0.236 | -0.035 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Reference price 2 | 1.830 | 4.550 | 1.300 | 0.575 | 0.805 | 1.690 | 1.690 | 1.690 |
| Nbr of stocks (in thousands) | 1,62,026 | 1,99,186 | 2,18,887 | 2,56,502 | 2,91,320 | 3,12,320 | 3,12,320 | - |
| Announcement Date | 18/03/21 | 25/02/22 | 28/02/23 | 16/04/24 | 05/03/25 | - | - | - |
1USD in Million2USD
Estimates
Upcoming events: Ocugen, Inc.
| 27/03/2026 | Q4 2025 Earnings Release (Projected) |
| 01/05/2026 | Q1 2026 Earnings Release (Projected) |
| 31/07/2026 | Q2 2026 Earnings Release (Projected) |
| 06/11/2026 | Q3 2026 Earnings Release (Projected) |
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | ||
|---|---|---|---|---|---|---|
 | - | - | -7.41x | - | - | |
| 0.88% | 1% | 38.88x | 4.01x | 5.65x | |
| - | - | - | - | - | |
| -.--% | -.--% | 33.47x | 6.37x | 3.33x | |
| -.--% | -.--% | 103.47x | 9.36x | 6.63x | |
| 0.35% | 0.36% | 55.18x | 2.64x | 11.32x | |
| -.--% | -.--% | -21.53x | 14.65x | 6248.57x | |
| - | - | - | - | - | |
| -.--% | -.--% | 41.27x | 41.21x | 6.69x | |
| - | - | - | - | - | |
| Average | 0.2% | 0.23% | 34.76x | 13.04x | 1,047.03x | |
| Weighted average by Cap. | 0.27% | 0.3% | 45.50x | 9.76x | 738.28x |
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Estimates Revisions
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Annual Profit -
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition